Not all HPV tests are designed equally.
Only the BD Onclarity™ HPV Assay provides you with the most comprehensive HPV test results available on the market today.# Get the information you need to more precisely assess her risk of cervical cancer.*1-7
The BD Onclarity™ HPV Assay is available out of BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test, the two most common Pap vials used by laboratories in the United States.
Did you know that the BD Onclarity™ HPV Assay is the only FDA-approved HPV
test that offers extended genotyping?†6,7
The BD Onclarity™ HPV Assay gives you comprehensive results…
Individual results for 6 HPV genotypes with highest risk for disease
Strategic grouped results for lower risk HPV genotypes
…so you can identify HPV 31, which poses a higher risk for developing cervical precancer than HPV 18.1
BD Onclarity™ HPV Assay is the only FDA-approved HPV test that provides an individual result for HPV 31.7
…so you can track genotype-specific HPV persistence for the most high-risk HPV genotypes, as compared to other FDA-approved HPV tests.6,7
Genotype-specific high-risk HPV persistence is the most important determinant of cervical cancer risk in women who test HPV positive.1,3-5
The BD Onclarity™ HPV Assay gives you reliable results…
BD Onclarity™ HPV Assay is designed to reduce the number of false-positive and false-negative results by using gene-specific PCR primers, and an internal control.6,7
…so you can feel confident in the results that you get and ultimately help improve your patient’s care experience.8
Less false-positives could mean less unnecessary colposcopies.8
Less false-negatives could mean less missed cervical disease.8
How do the other FDA-approved HPV tests compare?
Shape the future of cervical cancer screening with
the BD Onclarity™ HPV Assay
ThinPrep is a trademark of Hologic, Inc.
#BD Onclarity™ HPV Assay is the only FDA-approved HPV test that offers extended genotyping.
*As compared to other FDA-approved HPV tests.
†Extended genotyping refers to those high-risk HPV types beyond types 16 and 18 that may impact patients and lead to high cervical disease risk.
FDA; Food and Drug Administration; HPV, human papillomavirus.
1. Bonde JH et al. J Low Genit Tract Dis. 2020;24(1):1–13.
2. Stoler MH et al. Gynecol. Oncol. 2019; 153(1):26–33.
3. Elfgren K et al. Am J Obstet Gynecol. 2017;216(3):264.e1–7.
4. Radley D et al. Hum Vaccin Immunother. 2016;12(3):768–72.
5. Bodily J and Laimins LA. Trends Microbiol. 2011;19(1):33–9.
6. BD OnclarityTM HPV Assay US Package Insert [8089894].
7. Salazar KL et al. J Am Soc Cytopathol. 2019;8(5):284–92.
8. Perkins RB et al. J Low Genit Tract Dis. 2020;24:102–31.
Learn more about our BD Women’s Health solutions
This form is only intended for use by healthcare professionals seeking additional information about BD products and solutions. Patients seeking health and treatment information should contact their healthcare professional and can find additional resources from ACOG and the American Cancer Society.
Do not submit protected health information (PHI) or patient information (PII) through this form. If you do submit PHI or PII, your question may not be answered, as the information will be deleted to protect your privacy.